GPCRs: emerging targets for novel T cell immune checkpoint therapy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Immune checkpoint blockade (ICB) is a standard treatment for advanced solid organ malignancies, but its efficacy in stimulating anti-tumor immunity is limited.
• G-protein coupled receptors (GPCRs) are crucial regulators of the immune system, particularly in mediating T lymphocyte functions.
• Several novel GPCRs, including GPR171, lysophosphatidic acid receptors (LPARs), GPR68, cannabinoid receptor 2 (CB2), and prostaglandin E receptors, are implicated in immune regulation.

Purpose of the Study:

• To review the current understanding of novel immunoregulatory GPCRs in cancer.
• To explore the expression patterns, immune roles, and therapeutic potential of these GPCRs.
• To discuss future research directions for GPCR-targeted cancer immunotherapy.

Main Methods:

• Literature review of studies on GPCRs in cancer immunology.
• Analysis of GPCR expression patterns in various cancers.
• Evaluation of GPCR-mediated mechanisms in anti-tumor immune responses.

Main Results:

• Novel GPCRs demonstrate potential in mediating anti-tumor responses.
• These GPCRs can activate cytotoxic T cells, inhibit immunosuppressive lymphocytes, and enhance immune cell infiltration.
• Their roles are observed across multiple cancer types, suggesting broad applicability.

Conclusions:

• Novel GPCRs represent promising therapeutic targets for enhancing cancer immunotherapy.
• Targeting GPCRs could overcome limitations of current treatments like ICB.
• Further investigation into GPCRs' expression and function is warranted for developing novel cancer therapies.